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CANAVANINE ANALOGS AND THEIR USE 
AS CHEMOTHERAPEUTIC AGENTS 
CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is a continuation-in-part of application 
Ser. No. 08/353,270, ?led Dec. 5, 1994 now US. Pat. No. 
5,552,440 Which issued incorporated herein by reference in 
its entirety. 
TECHNICAL FIELD 
The invention relates to a pharmaceutical composition 
comprising canavanine analogs, and a method of treatment 
of cancer, particularly pancreatic cancer, With canavanine 
analogs. 
BACKGROUND 
L-Canavanine [L-2-amino-4-(guanidinooXy)butyric 
acid], a nonprotein amino acid found in certain leguminous 
plants37, is a structural analog of L-arginine in Which the 
terminal methylene group is replaced by oxygen. 
L-Canavanine, a substrate for arginyl-tRNA-synthetase, is 
incorporated into neWly synthesiZed protein in place of 
arginine to create structurally aberrant and dysfunctional 
proteins38. Available evidence supports the contention that 
an important biochemical basis for canavanine’s insecticidal 
and antitumor activities is the formation of dysfunctional 
canavanine-containing proteins.39>4O 
More than 26,000 people die each year in our country 
from pancreatic adenocarcinomal. Death is the inevitable 
consequence to more than 90% of patients With this disease. 
It is the fourth most common cause of cancer death in men 
and the ?fth most common for Women2. Overall, it is the 
fourth most common carcinoma after those of the lung, 
colon and breast3. The incidence of this disease is linear With 
age to siXty but its occurrence increases markedly in the 
seventh or eighth decade of life“. There are several different 
histologies associated With cancer of the pancreas including 
small cell cancer, cystadenocarcinoma, islet cell tumors, 
lymphoma and carcinoid; hoWever, 75—80% of the cases 
involve adenocarcinomas of ductal origins. The only de?ni 
tive risk factor in pancreatic cancer is cigarette smoking. A 
typical smoker accepts up to four times the risk of a 
nonsmoker6. 
Located in the upper abdomen in the retroperitoneum, the 
pancreas is associated intimately With many major structures 
including the portal vein, stomach, duodenum, common bile 
duct and the superior mesenteric artery. As the tumor groWs, 
the patient’s symptoms result from tumor in?ltration of 
surrounding structure causing pain, nausea, vomiting, 
Weight loss and jaundice. The latter condition presents 
symptoms in no more than one half of the patients. Once 
tumor in?ltration occurs other structures such as the portal 
vein become affected and this precludes curative resection 
ing of the pancreas. 
Effective treatment of pancreas cancer must achieve tWo 
dif?cult goals: control of the primary tumor mass, both 
initially and subsequently, and treatment of the metastatic 
tumor cells. As a result of its insidious onset, the diagnosis 
of pancreas cancer is delayed frequently for several months. 
This delay has profound implications, since metastatic 
spread to the liver or lymph nodes has been observed at a 
time of diagnosis in 60% of patients, and this factor dimin 
ishes the prospect for long-term survival7. Also, there are no 
knoWn speci?c markers of carcinoma of the pancreas and it 
is asymptomatic in its early stages. 
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Conventional Therapy for Pancreatic Cancer 
Currently, surgery is the primary and only curative 
therapy for pancreas cancer. HoWever, only 15—25% of 
tumors are resectable at the time of diagnosis9 and regret 
tably only 10—20% of patients resected Will survive more 
than tWo yearslo. With these less than satisfactory surgical 
results, present day therapy has evolved in tWo directions: 
palliation of symptoms and aggressive multimodality treat 
ment regimes Which combine surgery With chemotherapy 
and radiation treatment. 
Palliative therapy has become a major thrust of current 
treatment. Initial relief of symptoms has relied on surgery 
With surgical bypass of gastric outlet obstruction11 and 
operative bypass of biliary obstruction12. Subsequent symp 
tomatic treatment has centered around endoscopic place 
ment of biliary stents to bypass tumors blocking the biliary 
tract13 and/or percutaneous placement of bypass conduits14. 
Aggressive multimodality therapy combining chemo 
therapy and radiation therapy With surgery has been the 
response of choice When surgery alone Was not effective. 
Radiation has been the cornerstone of therapy for unresec 
table cancer of the pancreas and 5-?uorouracil (5-FU) 
chemotherapy has been an important adduct to radiation 
treatment in these patients15 . HoWever, despite these valiant 
efforts, no patient survives ?ve years. 
A single, small randomiZed trial shoWed signi?cant ben 
e?t from combined radiation and chemotherapy given tWo 
years after operation16. While this study Was limited by an 
inadequate number of patients, nonetheless there Was bene?t 
to patients receiving multi-modality treatment. 
Effective radiotherapy needs to maXimiZe eXposure of the 
affected tissues While sparing normal surrounding tissues. 
Interstitial therapy, Where needles containing a radioactive 
source are embedded in the tumor, has become a valuable 
neW approach. In this Way, large doses of radiation can be 
delivered locally While sparing the surrounding normal 
structures17. Intraoperative radiotherapy, Where the beam is 
placed directly onto the tumor during surgery While normal 
structures are moved safely aWay from the beam, is another 
specialiZed radiation technique. Again, this achieves effec 
tive irradiation of the tumor While limiting eXposure to 
surrounding structures. Despite the obvious advantage of 
approaches predicated upon local control of the irradiation, 
patient survival is not signi?cantly improvedls’lg. 
The foundation of chemotherapy for carcinoma of the 
pancreas has employed 5-FU2O. Here too, the prognosis is 
bleak; no better than 10—15% of patients treated With 5-FU 
Will experience a signi?cant reduction in tumor siZe; overall 
survival rates are not improved. The addition of other 
chemotherapeutic agents such as cis-platin or adriamycin 
has not dramatically improved disease managementzo). For 
this reason, attempts to augment the intrinsic activity of 
5-FU have been undertaken. On one approach, 5-FU is 
converted to 4-?uorodeoXyuridine monophosphate 
(FdUMP) Which binds covalently to thymidylate synthase 
(EC 2.1.1.45). This competitive inhibitor disrupts DNA 
replication by curtailing deoXyuridine monophosphate 
anabolism to deoXythymidine. 
Reduced folates such as leucovorin are a necessary cofac 
tor for FdUMP binding to thymidylate synthase21. Cancer 
cells depauperate in reduced folate are resistant to 5-FU 
chemotherapy, but that resistance can be circumvented by 
providing eXogenous reduced folate22. While 5-FU plus 
leucovorin relative to 5-FU alone has proven efficacious in 
treating colon cancer, patients With pancreas cancer received 
no bene?t by receiving these tWo drugs in combination23. 
5-Fluorouracil can also be converted to 5-?uorouridine 
monophosphate Which can be incorporated into mRNA 
5,859,295 
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thereby affecting protein translation. N-N- (phosphonacetyl) 
—L-aspartic acid (PALA) inhibits the transformation of aspar 
tic acid to orotidine monophosphate Which is converted 
subsequently to uridine monophosphate. The use of PALA 
provides a means of depleting essential uridine monophos 
phate. In the absence of uridine monophosphate, ?uorouri 
dine monophosphate is incorporated preferentially into 
mRNA Which promotes cell death. Preliminary data from 
experiments employing high dose (2,600 mg/m2) 5-FU after 
pretreatment With PALA have been promising, as signi?cant 
tumor reduction has been noted in 5 of 6 patients“. 
HoWever, subsequent phase II data have been less positive25 
With only one patient in 29 achieving any bene?t. While neW 
experimental efforts in treating pancreas cancer have been 
initiated, their limited success emphasiZes the need for 
radically neW approaches in the management of this devas 
tating disease. The present invention provides an additional 
alternative for the treatment of cancers, particularly pancre 
atic cancer, by providing for a pharmaceutical composition 
comprising canavanine, and a method of treatment of cancer, 
particularly pancreatic cancer With canavanine. 
DISCLOSURE OF THE INVENTION 
The present invention provides a method of treating 
pancreatic cancer by administering a pharmaceutically 
effective amount of a composition comprising canavanine 
analogs to a patient With pancreatic cancer. 
The canavanine analog compound may have a formula 
selected from: 
H Formula 1 
N 
[ >®—SCH2H5I9 
N 
H 
R1 is selected from SCH2H5I9; 
H Formula 2 
N 
[ \>—R2 
N 
H 
R2= SC2H5 
OCZHS; 
R F l 3 / 3 ormu a 
R4\ N 00c O—N=C/ 
>/\/ NHZ 
HN 
\R5 
Wherein 
R3 is H2; —(CH3)2; or H-Boc 
R4 is —CH2CH3; or —CH3 
R5 is H; H-Boc; or 
—CO ; 
1O 
15 
25 
35 
45 
55 
65 
and 
O Formula 4 
“ /NH2 HOOC C—N=C 
>/\/ \NHZ 
NH; 
O Formula 5 
O NH 
RrO ,' n \N% 2 
R2 R3 NH; 
NR3R4 Formula 6 
a 
The invention also provides a pharmaceutical composi 
tion comprising a pharmaceutically effective amount of a 
composition comprising canavanine analogs. 
In an alternative embodiment the invention provides a 
pharmaceutical composition comprising a canavanine ana 
log and 5-?uorouracil. 
In still another embodiment, the invention provides a 
pharmaceutical composition comprising canavanine and a 
compound selected from the group consisting of (S)-2 
aminoethyl-L-cysteine, L-2-aZetidine carboXylic acid, 
L-selenomethionine, L-3-[N-hydroXy-4-oXypyridyl]—2 
aminopropionic acid and mixtures thereof. 
The above and other objects of the invention Will become 
readily apparent to those of skill in the relevant art from the 
folloWing detailed description and ?gures, Wherein only the 
preferred embodiments of the invention are shoWn and 
described, simply by Way of illustration of the best mode of 
5,859,295 
5 
carrying out the invention. As is readily recognized, the 
invention is capable of modi?cations Within the skill of the 
relevant art Without departing from the spirit and scope of 
the invention. 
BRIEF DESCRIPTION OF DRAWINGS 
FIG. 1. The effect of canavanine enantiorners and chain 
length rnodi?cations on MIA-PaCa-2 cell viability. MIA 
PaCa-2 cells Were treated With the indicated concentration 
of: L-Canavanine (1, —O—), L-Hornocanavanine (2, —I—), 
D-Canavanine (3, G), or D-2-Arnino-3-(guanidinooXy) 
propionic acid (4, —A—) See teXt for additional experimental 
details. 
FIG. 2. The effect of structural rnodi?cation of the guani 
dinooXy group of L-Canavanine on MIA-PaCa-2 cell viabil 
ity. MIA-Pa-Ca cells Were treated With the indicated con 
centration of: L-Canavanine (1, -O-), L-2-Arnino-4-(1 
irnidaZolidenearninooXy) butanoic acid (8, —I-), or L-2 
arnino-4-[assyrn-NG, NG-dirnethyl(guanidinooXy)] butanoic 
acid (9, 
FIG. 3. The effect of L-canavanine esters on MIA-PaCa-2 
cell viability. MIA-PaCa-2 cells Were treated With the indi 
cated concentration of: L-Canavanine (1, -O-), 
L-Canavanine Methyl Ester 2HCl (10, 15-), L-Canavanine 
Ethyl Ester 2HCl (11,€-), L-Canavanine Isopropyl Ester 
2HCl (12, -El-), L-Canavanine n-Propyl Ester 2HCl (13, 
—I-), L-Canavanine n-Butyl Ester 2HCl (14, -Q), or 
L-Canavanaine n-Octyl Ester 2HCl (15, See teXt for 
additional experimental details. 
FIG. 4. Comparison of IC5O values of L-canavanine and 
some of its esters. 
O 
O NH; 
DESCRIPTION OF THE INVENTION 
The invention provides a pharmaceutical composition 
comprising a canavanine analog, and a method of treatment 
of cancer, particularly pancreatic cancer, With canavanine. A 
depiction of the basic canavanine rnolecule appears beloW. 
In addition to the amino acids Which are the building 
blocks of proteins, living systems also produce about 750 
nonprotein arnino acids26. These compounds possess a rich 
structural diversity and often elicit deleterious biological 
effects in viruses and all living systems”, L-Canavanine, the 
L-2-arnino-4-(guanidinooXy) butyric acid structural analog 
of L-arginine, is such a higher plant toXicant. Produced and 
stored by legurninous plants, canavanine is part of their 
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chemical defense, Where it functions as a barrier against a 
Wide array of insects and other pests28>29. 
Biochernical Basis for Canavanine’s Antirnetabolic Proper 
ties 
Studies With larvae of the tobacco horn Worrn, Manduca 
sexta, reveal that canavanine is an effective substrate for 
arginyl-tRNA synthetase. This canavanine-sensitive insect 
replaces on average at least one of three arginyl residues 
With canavanine in the de novo synthesiZed proteins of the 
hernolyrnph and body wall30 . 
Vitellin, an essential egg protein, is constructed by the 
gravid rnigratory locust, Locusta migratoria rnigratorioides 
[Orthoplera] from amino acids released by degradation of 
vitellogenin‘. Administration of canavanine to the female 
locust produces a canavanyl vitellogenin in Which 18 of the 
nearly 200 arginine residues are replaced by canavanine31; 
thus, canavanine occurs about once every 225 amino acids. 
In spite of this paucity in canavanine content, it elicits a 
profound alteration in vitellogenin structure best observed 
by electrophoretic analysis. 
Other chemical, physical, biochemical, and immunologi 
cal tests con?rrn the dramatic change in the three dirnen 
sional conforrnation resulting from canavanine assirnilation 
into this protein31. 
In response to microbial infection or mechanical injury, 
larvae of the rneat-eating ?y, Phormia terranovae, generate 
a group of antibacterial proteins knoWn trivially as the 
diptericins. If canavanine is included at the time of mechani 
cal injury, it is incorporated into neWly produced dip 
tericins32. Analysis of the diptericin activity of arginine- or 
canavanine-treated larvae reveals a nearly total loss of 
detectable biological activity for 3 of the 4 protective 
proteins-only diptericin A displays biological activity. Thus, 
canavanine incorporation into these protective proteins in 
place of arginine severely curtails their biological activity. 
Manduca sexta larvae respond to injected fragments of 
the cell Wall of Micrococcus lutea by producing lysoZyrne 
(EC 3.2.1.17), a protein Which cleaves the rnucopolysaccha 
ride framework of the cell Wall. Administration of 1 mg 
canavanine g-1 fresh larval Weight at the time of bacterial 
challenge generates canavanyl lysoZyrne With a ratio of 
canavanine to arginine of 1:38:02 (33). Canavanyl 
lysoZyrne exhibits a 50% loss of catalytic activity33. These 
insectan studies support the contention that the antirneta 
bolic effects of canavanine re?ect its incorporation into 
neWly synthesiZed proteins Which alter essential conforma 
tion and produces dysfunctional proteins. 
Canavanine may be produced by isolating the amino acid 
from jack beans by the method of KitagaWa, Tokiyarna, J. 
Biochern., (Tokyo) 11, 265 (1929) incorporated herein by 
reference in its entirety. See also Nyberg et al., J. Am. Chem. 
Soc., 79, 1222 (1957); Frankel et al., J. Am Chem. Soc., 
3127 (1963); and Yarnada et al., Agr., Biol. Chern., 37, 2201 
(1973) for additional methods of synthesis of canavanine, 
also incorporated herein by reference. 
Evaluation of Canavanine’s Antineoplastic Activity 
Canavanine’s ability to disrupt the groWth of rapidly 
dividing and groWing larval cells led to whole animal studies 
of its antineoplastic activity. The inventors found that cana 
vanine may be incorporated into key protein(s) unique to the 
cancer cell and that these structurally aberrant proteins, 
critical to the groWth and proliferation of the cancer cell, 
may be dysfunctional. 
EXAMPLE 1 
Employing a solid rat colonic carcinoma in Fischer F433 
rats, it was demonstrated that canavanine analogs of the 
5,859,295 
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invention possesses appreciable antineoplastic activity. For 
example, administration of a canavanine analog at a 3.0 g/kg 
dosing regimen for 5 consecutive days results in a 22% loss 
in tumor volume, While 9 days of daily dosing elicits a 60% 
diminution of the tumor“. 
HoWever, the canavanine analogs are cumulatively toxic 
and can result in a Weight loss of 19% in animals dosed With 
3.0 g/kg canavanine for 5 days“. Additional experimenta 
tion established unequivocally that the observed body 
Weight loss is not responsible for the canavanine analog 
compounds antitumor effects“). 
EXAMPLE 2 
Initial experimental efforts have been extended to deter 
mine if canavanine analog ef?cacy as an anticancer agent is 
increased in combination With 5-?uorouracil (5-FU). Pro 
viding a canavanine analog at 1.0 g/kg or 2.0 g/kg daily for 
5 consecutive days With 5-FU signi?cantly increases the 
antitumor activity of either drug alone (see FIG. 4). Body 
Weight loss experienced by canavanine-treated animals 
increases in those animals given both drugs. These studies 
evidence that combination therapy offers a viable means of 
improving canavanine analogs intrinsic ef?cacy. 
In order to improve canavanine analogs potential as 
chemotherapeutic agents, a number of canavanine analogs 
Were evaluated for enhanced antitumor ef?cacy and dimin 
ished groWth-inhibiting activity. 
EnZyme activity studies conducted, reveal a number of 
other nonprotein amino acids Whose assimilation into pro 
teins disrupts normal catalytic activity. Some natural prod 
ucts such a (S) -2-aminoethyl-L-cysteine, L-2-aZetidine car 
boxylic acid, L-selenomethionine, and L-3-[N-hydroxy-4 
oxypyridyl]-2-aminopropionic acid or mixtures thereof are 
not only very active but also interact With canavanine to 
signi?cantly amplify canavanine-mediated disruption of 
protein function”. 
Thus, there are a number of nonprotein amino acids 
besides canavanine able to substitute for their protein amino 
acid counterpart to generate dysfunctional proteins. These 
natural products often possess signi?cant antitumor poten 
tial alone, in combination With canavanine, and With other 
therapeutic drugs. 
The ability to assault the local cancer cell and even its 
metastatic offspring simultaneously With an array of non 
protein amino acid derivatives offers a Weapon of consid 
erable potential value. 
Canavanine’s Ef?cacy against Pancreatic Tumor 
Analysis of L-[guanidinoxy-14C] canavanine and other 
canavanine analog uptake into the protein of the major 
organs of the rat disclosed the highest radiolabeling in 
pancreatic proteins“. These proteins had 10 times the 
amount found in liver, muscle or brain samples. The ef?cient 
incorporation of radiolabeled canavanine into pancreatic 
proteins coupled With its demonstrated ability to create 
dysfunctional proteins prompted evaluation not only of 
canavanine but more importantly its derivatives as chemo 
therapeutic agents for human pancreas cancer. 
Abasic understanding of the biochemical basis for cana 
vanine’s antimetabolic properties has emerged over the past 
?ve years and these efforts have permitted development of 
a sound rationale for derivative synthesis. Chemical syn 
thetic efforts, detailed herein, hold the promise of providing 
drugs With markedly enhanced ef?cacy and permit their 
administration at signi?cantly loWer dose levels than those 
required by canavanine. It has been unequivocally estab 
lished that a 1 g kg'1 dose of canavanine has no adverse 
effect on body Weight nor on other discernible parameters of 
the rat. 
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A chemotherapeutic strategy predicated upon controlling 
cancer cell groWth through the formation of structurally 
aberrant, dysfunctional proteins has been developed. Such 
macromolecules deny the cancer cell essential metabolites, 
undermine regulatory and other cellular control elements 
and pervasively disrupt critical cellular groWth-related pro 
cesses. Current treatment practices have not enjoyed sub 
stantial success and a radical neW approach is justi?ed. The 
approach of the invention is one With a strong biochemical 
foundation that provides a sound rationale for the develop 
ment of neW derivatives for use as chemotherapeutic agents. 
Most importantly, the canavanine analogs’ mode of action is 
not directed at DNA replication, events that occur prior to 
transcription of the message, nor at message translation. 
The present strategy for developing an effective chemo 
therapeutic agent does not focus on nucleic acid metabolism 
but rather at the level of protein function. 
Evaluation of Drug Efficacy 
A number of cell lines derived from pancreatic ductal 
adenocarcinoma have been established, including CFPAC-1 
(ATCC CRL 1918), PANC-1 (ATCC CRL 1469), MIA 
PaCa-1, and MIA-PaCa-2 (ATCC CRL 1420). MIA-PaCa2 
is highly tumorigenic, has lost the ability to be groWth 
regulated, and is derived from metastatic cells. CFPAC-1, 
Which is derived from a primary tumor line, is the faster 
groWing cell line and is preferable for Whole animal studies. 
The availability of each of these lines from the American 
Type Culture Collection, 12301 ParklaWn Drive, Rockville, 
Md., USA, insures an effective means for initial screening of 
neWly synthesiZed derivatives both alone and in combina 
tion With other developed compounds as Well as With drugs 
employed presently in human chemotherapy. The most 
promising candidates are employed in Whole animal evalu 
ation involving nude mice. 
This invention permits an effective transition from labo 
ratory ?ndings and evaluations to their bene?cial employ 
ment in alleviating the human suffering associated With this 
dreadful disease. 
EXAMPLE 3 
Antitumor Effect of Canavanine analogs in the Male Fischer 
Rat 
The marked antitumor effect of canavanine analogs Was 
demonstrated initially by our research group in studies on a 
solid, colonic carcinoma in male Fischer 344 rats. Admin 
istration of 3 g/kg canavanine analogs reproducibly pre 
vented tumor groWth during 5 or 9 consecutive treatment 
days. In fact, the ?nal fresh tumor Weight Was typically 10% 
less than the Weight of the initial tumor34. 
To enhance canavanine’s antineoplastic activity, it Was 
tested in combination With 5-FU. Providing canavanine at 
1.0 g/kg or 2.0 g/kg daily for 5 consecutive days With 5-FU 
signi?cantly increased the antitumor activity of either drug 
alone. This Whole animal study Was of considerable impor 
tance because it demonstrated that combination therapy 
offers a viable mean of improving canavanine’s intrinsic 
ef?cacy and supports the contention that canavanine and its 
derivatives in conjunction With 5-FU may offer an effective 
chemotherapeutic strategy. Alternatively, canavanine 
therapy may be combined With radiotherapy. 
EXAMPLE 4 
The Effect of Canavanine on MIA-PaCa-I Cells 
Work has been performed to evaluate the effect of cana 
vanine on MIA-PaCa-1 cells. Cell survival Was determined 
by the ability of viable cells groWn on Dulbecco’s modi?ed 
medium to reduce tetraZolium dye to a colored formaZan 
product. The experiment depicted in FIG. 4 dramatically 
discloses the potent ef?cacy of canavanine against these 
cells. 
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That the antitumor potential of canavanine analogs is 
related directly to the competing arginine concentration. 
This ?nding is of great importance because it reveals that 
canavanine is functioning as an effective arginine antagonist. 
This point is seminal to our contention that the antitumor 
effect of canavanine is related to its competition With argi 
nine for arginyl-tRNA synthetase. 
EXAMPLE 5 
The Antineoplastic Effect of Canavanine in the Nude Mouse 
Experiments With athymic nude mice Were conducted 
With 6 treated and control mice. The palpable CFPAC-1 
derived tumors greW sloWly but after 28 days appreciable 
tumor groWth had occurred in all experimental animals 
(FIG. 6A). By contrast, the CPFAC-1-derived tumors exhib 
ited little groWth in canavanine-treated animals (FIG. 6B). In 
2 of the 7 experimental animals, a precipitous decline in 
tumor volume Was observed during the ?rst treatment Week. 
These exciting experimental results add further support to 
the fact that canavanine and its derivatives possess consid 
erable potential for the treatment of human pancreatic car 
cinoma. 
A number of structural analogs of L-canavanine [L-2 
amino-4-(guanidinooxy) butyric acid] the 6-oxa analog of 
L-arginine, have been synthesiZed and their groWth 
inhibitory effects evaluated in cultured MIA-PaCa-2 pan 
creatic carcinoma cells by the 3- (4.5-dimethylthiaZol-2-yl) 
-2,5-diphenyltetraZolium bromide (MTT) assay. The results 
indicate that D-canavanine and analogs in Which the carbon 
chain-length and/or terminal guanidinooxy functional group 
has been modi?ed elicit less groWth inhibitory activity than 
L-canavanine. On the other hand, several ester derivatives of 
L-canavanine have markedly enhanced groWth inhibitory 
activity compared to L-canavanine. Thus, esteri?cation con 
stitutes an effective structural modi?cation Which signi? 
cantly ampli?es the groWth inhibitory properties of the 
parent compound against MIA-PaCa-2 cells. 
L-Canavanine at 3.0 g/kg daily dose for 5 days elicits 
signi?cant inhibition of rat colon carcinoma, causing a 22% 
loss in tumor volume. A 60% loss in tumor volume is 
observed for a similar 9-day treatment period. HoWever, 
during this treatment, L-canavanine exhibits signi?cant 
cumulative toxicity in the form of Weight loss of 19%36>41. 
Additional experiments have established that the reduction 
in tumor volume is not related to the observed body Weight 
loss. Preliminary studies in nude mice carrying pancreatic 
ductal adenocarcinoma (CFPAC-1), shoW a signi?cant 
decrease in ?nal tumor volume after dosing animals With 
palpable tumors With 4 g/4 kg canavanine for 28 consecutive 
days. Canavanine proved even more effective When it Was 
provided on a comparable dosing schedule Which com 
menced 1 day after tumor cell implantation42. These studies 
reveal that canavanine is an effective chemotherapeutic 
agent for the treatment of pancreatic cancer. 
On-going investigation of canavanine’s antineoplastic 
activity demonstrates the value of developing canavanine 
analogs With diminished toxicity and enhanced potency. 
This application also describes synthetic methods for pre 
paring a number of L-canavanine derivatives and evaluates 
their groWth-inhibitory potency against cultured MIA 
PaCa-2 cells. 
Modi?cations of the canavanine molecule are based on 
the folloWing considerations. First, since x-ray crystallo 
graphic studies have revealed that the interatomic distance 
betWeen the [3-carbon and the carbon of the guanidino group 
of canavanine is someWhat shorter than that in the arginine 
molecule43, an insertion of an extra methylene group into the 
canavanine molecule While retaining the important guani 
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dinooxy functional group Was considered to be an effective 
alteration Which might result in an increase in af?nity for the 
arginyl-tRNA synthetase active site. Similarly, the chain 
shortened analog, in Which only one methylene group is 
present in the molecule Was evaluated. Second, it is reason 
able to contend that the antitumor activity of canavanine is 
stereospeci?c for the L-isomer, since arginyl-tRNA syn 
thetase Would undoubtedly recogniZe only the L-enantiomer 
of arginine as a substrate. Hence, the biological activity of 
the D-enantiomer of canavanine Was pursued to determine if 
it exhibited MIA-PaCa-2 cell groWth-inhibitory activity and 
to compare the activity of this stereoisomeric form With that 
of its naturally occurring antipode. It Was believed that 
D-canavanine Would not be an arginyl-tRNA synthetase 
substrate; thus, any adverse effects noted With D-canavanine 
could not result directly from its incorporation into neWly 
synthesiZed protein. In this respect, the D-enantiomer offers 
a means of evaluating canavanine’s activity divorced from 
its role in protein synthesis. Third, ionic and hydrogen 
bonding interactions of the guanidino group of arginine With 
neighboring amino acid residues are crucial for establishing 
the three-dimensional structure of a protein; replacement of 
this moiety With the guanidinooxy moiety of canavanine 
results in the formation of aberrant and dysfunctional 
protein.3o’44 Thus, analogs in Which the guanidinooxy group 
has been further modi?ed appears to cause a greater delete 
rious effect on the tertiary/quatenary structure of arginyl 
containing proteins than does canavanine. Thus, the effect of 
structural alteration of the terminal guanidinooxy group of 
L-canavanine Was also evaluated. 
Finally, the methyl, ethyl, isopropyl, n-propyl, n-butyl, 
and n-octyl esters of L-canavanine exhibit greater lipophi 
licity than canavanine and appear to possess improved cell 
membrane penetration properties. These compounds can 
constitute prodrug candidate forms of L-canavanine, and can 
be attacked by cytosolic esterases to generate the parent 
compound. 
Chemistry 
L-2-Amino-5-(guanidinooxy)pentanoic acid (L-HMCAV, 
homocanavanine; 2) and D-canavanine (D-CAV); 3) Were 
synthesiZed from D-methionine and L-glutamic acid 
5 -methyl ester respectively, as reported in Rosenthal et al.45 . 
The shortened chain-length analog of D-canavanine, D-2 
amino-3-(guanidinooxy)propionic acid (D-GOA, 4) Was 
synthesiZed via ring opening of D-cycloserine (5) to give 
D-2-amino-3-(aminooxy)propionic acid (6), folloWed by 
Zinc-mediated guanidination With cyanamide (Scheme 1). 
Structural alteration of the guanidinooxy group of 
canavanine, as in the ethylene (L-ETCAV, 8) or dimethyl 
analog (L-DMCAV, 9), Was achieved by reacting the copper 
salt of L-canaline (7) With 2-ethoxyimidaZoline or 
dimethylcyanamide, respectively (Scheme 2). 
L-Canavanine esters Were produced by heating 
L-canavanine (L-CAV, 1) With the appropriate anhydrous 
alcohol saturated With HCl gas. 
DETAILED DESCRIPTION OF THE FIGURES 
As shoWn in FIG. 1, cell viability assays indicate that 
alteration of the number of methylene groups betWeen the 
amino [3-carbon and the guanidinooxy group does not 
enhance the groWth-inhibitory effects of the parent com 
pound in cultured MIA-PaCa-2 cells. Decreasing the num 
ber of methylene groups from 2 to 1, in addition to inverting 
the stereochemistry at C-2 (D-GOA, 4) results in almost 
complete loss of groWth-inhibitory activity When compared 
to that of L-canavanine. An increase in methylene group 
number from tWo to three (L-homocanavanine, L-HMCAV, 
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2) affords a compound that exhibits only Weak growth 
inhibitory properties. These results are consistent With the 
belief that chain shortening produces an analog less likely to 
be recognized as a substrate for arginyl-tRNA synthetase 
and Would therefore not be ef?ciently incorporated into 
protein. The results obtained for the chain-lengthened ana 
log suggest that a crucial intra-atomic distance is required 
betWeen the amino acid functionality and the terminal 
guanidinooxy moiety for recognition by the amino acyl 
synthetase enZyme. 
The D-isomer of canavanine (3) exhibits a Weak but 
signi?cant decrease in groWth-inhibitory activity against 
MIA-PaCa-2 cells, and Was similar in potency to the chain 
elongated L-homocanavanine Thus, the L-isomer of 
canavanine is signi?cantly more effective in the groWth 
inhibitory activity than the D-isomer, Which may re?ect the 
different abilities of these enantiomers to be incorporated 
into arginyl-containing protein. The groWth inhibiting activ 
ity of D-canavanine also suggests that D-canavanine’s anti 
metabolic properties result from factors other than aberrant, 
canavanyl protein formation. 
Structural modi?cation of the guanidinooxy functional 
group (8 and 9) affords compounds With signi?cantly 
reduced groWth inhibitory activity against cultured MIA 
PaCa-2 cells, as compared to L-canavanine (FIG. 2). The 
assym-NG, NG-dimethyl analog (9) exhibits Weak groWth 
inhibitory properties and is slightly less active than the NG, 
NG-ethylene analog The results suggest that an intact 
guanidinooxy group is required for maximum groWth 
inhibitory activity. 
The methyl, ethyl, and n-propyl esters (10, 11, 13) of 
canavanine exhibit slightly improved groWth-inhibitory 
activities in MIA-PaCa-2 cells With IC5O values of 0.79, 
0.67, and 0.62 mM, respectively, When compared to 
L-canavanine (IC5O value=1.33 mM, FIG. 3 and 4). 
Interestingly, the n-butyl and n-octyl esters of 
L-canavanaine (14, 15) elicit the most signi?cant increase in 
groWth inhibitory activity With IC5O values of at 0.32 and 
0.24 mM, respectively. This improved potency may be due 
to the increased lipophilicity and enhanced membrane 
penetrational properties of the ester analogs. 
When compared to L-canavanine, the isopropyl ester (12), 
Whose IC5O is 1.27 mM, also shoWs a slight increase in 
groWth inhibitory activity up to a concentration of 1.5 mM; 
at higher concentrations, this ester Was less active than 
L-canavanine. Compared to the other esters that Were 
evaluated, the isopropyl ester is more sterically hindered 
around the carbonyl moiety of the ester functionality and 
therefore more resistant to enZymatic hydrolysis, this factor 
appears to account for its loWer overall activity. Since 
ZWitterion formation is not possible for esters of amino 
acids, these esters shoWed enhanced lipophilicity and better 
transport characteristics than the parent amino acid. This 
property may provide a basis for the development of effec 
tive prodrug analogs of L-canavanine that possess greater 
bioavailability. 
EXAMPLE 6 
Human Pancreatic Carcinoma Cell Culture and Cell Viabil 
ity Assays 
Human pancreatic carcinoma cells (MIA-PaCa-2) Were 
purchased from the American Type Cell Collection (ATCC). 
The cells Were groWn in Dulbecco’s Modi?ed Eagle’s 
Medium (DMEM) containing 10% (v/v) fetal calf serum. 
Cell viability assays Were performed With MIA-PaCa-2 
cells in culture at the folloWing drug concentrations: 0.16, 
0.31, 0.62, 1.25, 2.5, 5.0, and 10.0 mM. The drugs Were 
dissolved into and diluted With DMEM. 
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Cell viability Was assessed by the metabolic 3-(4,5 
dimethylthiaZol-2-yl)-2,5-diphenyltetraZolium bromide 
(MTT) assay previously described by Kissane5 With minor 
modi?cations. The metabolic MTT assay measured the 
ability of viable cells to reduce a tetraZolium dye to a 
formaZan chromogen, Which could be measured at 630 nm. 
MIA-PaCa-2 cells, maintained in exponential groWth for up 
to 72 hr. Were plated at 5><103 cells/Well in a 96-Well plate. 
The cells Were alloWed to groW for 24 h. prior to drug 
addition. Four replicate Wells Were used for the drug-free 
control and for each drug concentration. MTT assays Were 
performed 48 h. after addition of the drug. Viability Was 
calculated as the percentage of the drug-free control cell 
population 1 SEM. 
Silica gel plates (2.5><7.5 cm, 250 pm layer, ?uorescent at 
254 nm) Were purchased from Diamond Whatman 
International, Ltd. (Clifton, N.J Column chromatographic 
separations Were carried out With silica gel (200—400 mesh, 
60 from Fisher/Aldrich (Milwaukee, Wis.). Chemicals 
and solvents Were secured from Fisher/Aldrich Chemical 
Co. Melting points Were recorded on a Fisher-Johns melting 
point apparatus, and are uncorrected. 1H-NMR and 13C 
NMR spectra Were carried out on a Varian VXR-300 MHZ 
spectrometer (Palo Alto, Calif.); spectra Were run at 21° C. 
in either CDCl3, DMSO-d6, or D20 using tetraethyl silance 
(TMS) or the sodium salt of 3-(trimethyulsilyl) propionic 
2,2,3,3-d4 acid (TSP) as an internal standard. Elemental 
analyses Were performed by Atlantic Microlabs (Norcross, 
Ga.), [ot]D23 values Were observed at 589 nm and determined 
on a Perkin-Elmer 241 polarimeter. MS data Were carried 
out on a Kratos concept 1H MS50 spectrometer. 
EXAMPLE 7 
D-2-Amino-3-(aminooxy)propionic acid 
dihydrochloride (6) 
D-Cycloserine (5, 408 mg. 4 mmol) Was dissolved in 2N 
HCl (20 mL); the resulting solution Was kept at 60° C. for 
6 h. After cooling to 00 C., the solution Was adjusted to pH 
4.5 With 15% (W/v) NaOH and Was applied to a 25 cm3 
DoWex 50x8 (H+) column. The resin Was Washed With 
deioniZed Water (500 mL) folloWed by 5N NH 4OH (80 mL). 
The column effluent Was concentrated by rotary evaporation 
in vacuo to give 6 (480 mg, 99% yield) as a colorless solid, 
mp. 167.0°—169.5° C.; [a]D23=+24.5° (c=2.15, H2O); 
1H-NMR (D20); 64.79 (dd, J=11.0, 5.2 HZ, 1H, 3-CH2a) 
4.62 (dd, J=11.0, 3.0 HZ, 1H, 3-CH2b), 4.55 (dd, J=5.2, 3.0 
HZ, 1H, 2-CH) ppm; 13C-NMR (D20): 6170.95 (C-1), 74.19 
(C-3), 54.41 (C-2) ppm; Anal (C3H1OCl2N2O3) C, H, N, Cl. 
EXAMPLE 8 
D-2-Amino-3 (guanidinooxy)propionic acid (4) 
Copper oxide (750 mg) Was added to a solution of 6 (480 
mg, 4 mmol) in distilled Water (5 mL). The mixture Was 
heated for 5 min at 100° C., for 2 h. at 50° C., and for 24 h. 
at 23° C. The unreacted CuO Was ?ltered, and the ?ltrate 
Was adjusted to pH 9.2 With 1N NaOH. This solution Was 
then added to a solution of cyanamide (190 mg, 4.60 mmol) 
and ZnCl2 (705 mg, 5.2 mmol) dissolved in a minimum 
amount of Water. The resulting mixture Was stirred at 50° C. 
for 3 days. The reaction Was terminated by bubbling hydro 
gen sul?de through the reaction mixture for 10 min; the 
resulting precipitate Was ?ltered. The ?ltrate Was evaporated 
to dryness by rotary evaporation in vacuo to give 300 mg of 
crude product (45% yield). Part of this product Was then 
applied to a cellulose column (15x1 cm) and eluted With 
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ethanol: 0.2N NH4OH (70:30). The last eluting fraction Was 
evaporated to dryness to give pure 4 as a glassy solid; 
[ot]D23=+7.5° (c=1.35, H2O); 1H-NMR (D20): 64.28 (dd, 
J=6.0, 3.6 HZ, 1H, 2-CH), 4.14 (dd, J=11.0, 3.6 HZ, 1H, 
3-CH2a), 4.08 (dd, J=11.0, 6.0 HZ, 1H, 3-CH2b) ppm; 
13C-NMR (D20): 6177.14 (C-1), 159.42 (C=N) 75.63 
(C-3), 58.91 (C-2) ppm. 
EXAMPLE 9 
L-2-Amino -4(1 -imidaZolideneaminooxy)butanoic 
acid (8) 
The ethylene analog of canavanine 8, Was obtained by 
treatment of the copper salt of L-canaline (1 mmol, 7), 
prepared as described for 4, With 2-ethoxyimidaZoline (240 
mg, 1.8 mmol) in Water (5 mL) at 45° C. for 4 days. After 
adjusting the solution to pH 5.0 With 1N NaOH, hydrogen 
sul?de Was bubbled through for 5 min. The acidic reaction 
mixture Was ?ltered and the ?ltrate adjusted to pH 3.4 With 
1N NaOH. This solution Was applied to a 25 cm3 column of 
DoWex 50><8 (NH 4") and the resin Was Washed With distilled 
Water (500 mL) folloWed by 0.2N NH4OH (400 mL). The 
ammonia Wash Was evaporated to dryness by rotary evapo 
ration in vacuo, and the resulting residue Was puri?ed by 
cellulose column chromatography (25 x1 cm) by elution With 
n-BuOH:AcOH:H2O (4:1:1). Fractions containing 8 Were 
combined and the solvent Was removed by rotary evapora 
tion in vacuo to give pure 8 (29 mg, 16%) as a glassy solid; 
[a]D23=+9.6° (c=2.4, H2O); 1H-NMR (D20): 64.08—4.17 
(m, 2H, 4-CH2), 3.90 (t, J=6.0 HZ, 1H, 2-CH), 3.80 (s, 4H, 
NCHZCHZN), 2.27 (dt, J=6.0 HZ, 2H, 3-CH2) ppm; 13C 
NMR (CDCl3): 6176.66 (C-1), 164.09 (C=N), 75.72 (C-4), 
54.99 ((3-2), 45.75 (ZXNCHQ), 3151 ((3-3) ppm; HRFABMS 
calcd. for C7H14N4O3 203.1144 (MH+), found 203.1128. 
EXAMPLE 10 
L-2-Amino-4-[assym-NG, NG-dimethyl 
(guanidinooxy)] butanoic acid (9) 
Compound 9 (71% yield) Was obtained as a colorless 
solid utiliZing the procedure described for the preparation of 
8, but using dimethylcyanamide in place of 
2-ethoxyimidaZoline, m.p. 175.0°—177.0° (dec.); [a1D23=+ 
4.6° (c=1.6, H2O); 1H-NMR (D20): 63.98 (t, J=6.0 HZ, 2H, 
4-CH2), 3.82 (t, J=6.0 HZ, 1H, 2-CH), 2.82 (s, 6H, 2><CH3) 
ppm; 13C-NMR (D20): 6177.90 (C-1), 162.80 (C=N), 
72.26 (C-4), 55.39 (C-2), 39.49 (2><CH3), 32.73 (C-3) ppm; 
Anal. (C7H16N4O3.0.25H2O) C,H,N. 
EXAMPLE 11 
L-Canavanine Esters 
The methyl, ethyl, isopropyl and n-propyl esters of cana 
vanine (10—13) Were prepared by heating a solution of 
L-canavanine (1, 1 mmol) in the appropriate anhydrous 
alcohol (6 mL) saturated With dry HCl at 80° C. for 1 h. The 
reaction mixture Was ?ltered and the ?ltrate removed by 
rotary evaporation in vacuo to give a clear, gummy residue. 
The residue Was triturated With anhydrous ether (2 mL) and 
the solvent decanted off. The resulting solid Was then dried 
under high vacuum (0.5 mm Hg). The n-butyl and n-octyl 
esters of canavanine (14,15) Were similarly prepared With 
the folloWing modi?cations: the heating time Was increased 
to 3 h. in 17% HCl/anhydrous 1-butanol (W/W) and 24 h. in 
11% HCl/anhydrous 1-octanol (W/W), respectively. The 
method for preparing the octyl ester of canavanine is 
described in detail in the experimental section. 
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EXAMPLE 12 
Methyl L-2-amino-4-guanidinooxybutanoate (10) 
Compound 10 Was obtained as a White hygroscopic solid 
(71% yield); [a]D23=+19.5° (c=0.45, H2O); 1H-NMR 
(DMSO-d6): 68.90 (br s, 3H, NH3+), 7.80 (s, 5H, C(N 
HQNHJ), 4.10 (br s, 1H, 2-CH), 3.80—4.00 (m, 2H, 4-CH2), 
3.70 (s, 3H, OCH3), 2.00—2.30 (m, 2H, 3-CH2) ppm; 13C 
NMR (DMSO-d6): 6169.29 (C-1), 158.39 (C=N), 71.87 
(C-4), 52.90 (CH3), 48.88 (C-2), 28.14 (C-3) ppm; Anal. 
(C6H16Cl2N4O3.1 H2O.0.1 CH3OH) C, H, N, Cl. 
EXAMPLE 13 
Ethyl L-2-amino-4-guanidinooxybutanoate (11) 
Compound 11 Was obtained as a White hygroscopic solid 
(75% yield); [a]D23=+18.3° (c=0.52, H2O); 1H-NMR 
(DMSO-d6): 69.00 (br s, 3H, NH3+), 7.83 (s, 5H, C(N 
HQNHJ), 4.18(q, J=6.5 HZ, 2H OCH2CH3), 4.10 (t, J=6.5 
HZ, 1H, 2-CH), 3.85—4.00 (m, 2H, 4-CH2), 2.10—2.30 (m, 
2H, 3-CH2) ppm; 13C-NMR (DMSO-d6): 6169.12 (C-1), 
158.63 (C=N), 72.11 (C-4), 62.00 (QHZOOC), 49.17 (C-2), 
28.42 (C-3), 13.99 (QHBCHZ) ppm; Anal. 
(C7H18Cl2N4O3.0.8 H2O. 0.12 CZHSOH) C, H, N, Cl. 
EXAMPLE 14 
Isopropyl L-2-amino-4-guanidinooxybutanoate (12) 
Compound 12 Was secured as a White hygroscopic solid 
(54% yield); [a]D23=+16.1° (c=0.54, H2O); 1H-NMR 
(DMSO-d6): 69.00 (br s, 3H, NH3+), 7.84 (s, 5H, C(N 
H2)(NH3+)’ 4.98 (sept, J=6.5 HZ, 1H OCH), 4.06 (t, J=6.0 
HZ, 2-CH), 3.90—4.00 (m, 2H, 4-CH2), 2.10—2.25 (m, 2H, 
3-CH2), 1.22 (d, J=6.0 HZ, 6H, 2><CH3) ppm; 13C-NMR 
(DMSO-d6): 6168.58 (C-1), 158.59 (C=N), 72.03 (C-4), 
69.90 (QH(CH3)2), 49.17 (C-2), 28.40 (C-3), 21.41, 21.32 
(2><CH3) ppm; Anal. (C8H2OCl2N4O317 H2O) C, H, N, Cl. 
EXAMPLE 15 
n-Propyl L-2-amino-4-guanidinooxybutanoate (13) 
Compound 13 Was obtained as a White hygroscopic solid 
(96%); [a]D23=+28.7° (c=0.48, H2O); 1H-NMR (DMSO 
d6): 68.20—9.20 (br s, 3H, NH3+), 7.80 (s, 5H, C(NH2)N 
H3’), 4.08—4.22 (m, 2H, OCH2) 3.94—4.04 (t, 1H, 2-CH), 
3.81 (2H, 4CH2), 2.08—2.32 (m, 2H, 3-CH2), 1.58—1.72 (m, 
2H, OCHZCHZ), 0.88—0.96 (t, 3H, CH3) ppm; 13C-NMR 
(DMSO-d6): 6169.09 (C-1), 158.36 (C=N), 71.95 (C-4), 
67.22 (CHZO), 49.05 (C-2), 28.30 (C-3), 21.24 ( 
QHZCHZO), 10.11 (CH3) ppm; Anal. (C8H20Cl2N4O311 
H2O.0.16 C3H7OH) C, H, N, Cl. 
EXAMPLE 16 
n-Butyl L-2-amino-4-guanidinooxybutanoate (14) 
Compound 14 Was obtained as a White hygroscopic solid 
(91% yield); [a]D23=+16.7° (c=0.88, H2O); 1H-NMR 
(DMSO-d6): 68.20—9.20 (br s, 3H, NH3+), 7.80 (s, 5H, C(N 
H2)NH3+), 4.18 (m,2H,(OCH2), 4.00 (t, 1H, 2-CH), 3.35 
(t,2H, 4-CH2, overlap With Water peak), 2.08—2.28 (m, 2H, 
3-CH2), 1.54—1.64 (m, 2H, OCHZCHZ) 1.26—1.44 (m, 2H, 
OCHZCHZCHZ), 0.84—0.94 (t, 3H, CH3) ppm; 13C-NMR 
(DMSO-d6): 6169.08 (C-1), 158.32 (C=N), 71.91 (C-4), 
65.46 (CHZO), 49.06 (C-2), 29.84 (QHZCHZO), 28.29 (C-3), 
18.35 (QHZCHZCHZO), 13.41 (CH3) ppm; Anal. 
(C9H22Cl2N4O3.0.75 H2O. 0.25 C4H9OH) C, H, N, Cl. 
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EXAMPLE 17 
n-Octyl L-2-amino-4-guanidinooxybutanoate (15) 
L-canavanine (0.20 g, 1.13 mmol) Was heated in 5 mL of 
11% HCl/anhydrous octanol (W/W) at 80° C. for 24 h. The 
resulting mixture Was ?ltered. The solvent Was removed 
under high vacuum With gentle heating at 50°—60° C. The 
viscous residue Was dissolved in 1 mL of Water and the 
resulting solution Was lyophiliZed. Aclear hygroscopic (0.04 
g) residue Was obtained (10% yield); [ot]D23=+7.6° 
(c=0.485, H2O); 1H-NMR (DMSO-dG): 68.80—9.60 (br s, 
3H, NH,*), 7.80 (s, 5H, C(NH2)NH3+), 4.12420 (t,2H, 
OCHZ), 3.92—4.00 (t, 1H, 2-CH), 3.35 (t, 2H, 4-CH2, overlap 
With Water peak), 2.04—2.24 (m, 2H, 3-CH2), 1.56—1.66 (m, 
2H, OCHZCHZ), 1.22—1.38 (m, 10H, OCH2CH2(CH2)5), 
0.82—0.90 (t, 3H, CH3) ppm; 13C-NMR (DMSO-dG): 
6169.10 (C-1), 158.33 (C=N), 71.91 (C-4), 65.72 (CHZO), 
49.06 (C-2), 31.11, 28.47, 28.46, 28.31, 27.81, 25.07, 21.96 
(C-3 and (QH2)6CH2O), 13.85 (CH3) ppm. Anal. 
(C13H3ON4O3Cl2 0.95 H2O. 0.04 C8H17OH) C, H, N, Cl. 
Synthesis of Analogs of Canavanine 
Scheme 1: Synthesis of D-2-amino-3-(guanidinooxy) pro 
pionic acid (D-GOA) 
H 
O N \ O 2N HCl 
L 
NH; 
5 
O NH CuO, HZNCN 
2 %HO“ O/ ZnClg, HZS 
H‘ NH; 
6 
O NH; 
NR/ 
HO , o/ NHz 
' NH; 
4 
Scheme 2: Synthesis of L-2-amino-4-(1-imidaZolidene 
aminooxy) butanoic acid (L-ETCAV) and L-2-amino-4 
[assym-NG, NG-dimethyl (guanidinooxy)]butanoic acid 
(L-DMCAV) 
HO 
CuO, ZnClZ, H25 
1) Synthesis of N,N‘-ethylene canavanine 
10 
15 
20 
25 
30 
35 
40 
45 
65 
16 
A) 
(1) (2) 
10.5 (0.10 mol) of N,N‘-ethylenethiourea (98%) Was 
suspended in 50 ml of EtOH (abs.). EtI (16.7 g, 0.11 mol) 
Was added into this suspended solution. The reaction mix 
ture Was re?uxed for 2 hours. After cooling the solution to 
RT, 50 ml of ethyl ether Was added and the mixture Was 
cooled to 40° C. and stayed for 3 hours at 4° C. The mixture 
Was ?ltered and the solid Was Washed With ethyl ether. Yield 
21.2 g (82.5%) of 
B) 
(2) (3) 
5.0 g (0.085 mol) of KOH Was dissolved in 20 ml of EtOH 
(abs.) and 21.2 g (0.084 mol) of (2) Was added into this 
solution. The mixture Was stirred for 30 min. at RT, and 100 
ml of Water Was added. The mixture Was extracted With 
DCM (3><100 ml). The combined DCM solution Was Washed 
With Water (3><200 ml) and dried over Na2SO4. Solvent Was 
evaporated, to yield an oily residue of 
C) 
(3) (4) 
6.9 g (0.3 mol) of Na (metal) Was dissolved in 100 ml of 
EtOH (abs.) and the solution Was cooled to RT. Then the 
O H 
N 
0 
HO ,' \N 
NH2 
8 N 
H 
above oily residue of (3) Was added into the ethyl alcohol 
solution and the mixture Was re?uxed for 72 hours. The 
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solution Was cooled to RT and 100 ml of Water Was added. 
The mixture Was extracted With DCM (3><100 ml.), dried 
over Na2SO4. The solvent Was evaporated. The yield of (4) 
Was 6.79 g (71.4%). 
D) 
L-Canaline 
NH 
N,N'—ethylene—L-canaline 
536 mg (4 mmol) of canaline Was dissolved in 7 ml of 
Water, and 954 mg (12 mmol) of CuO Was added. The 
suspended solution Was boiled for 5 min, then stirred for 2 
hours at 50° C. and for 20 hours at RT. The excess CuO Was 
removed by ?ltration. The pH of the solution Was adjusted 
to 9.2 With 1N NaOH. 1.04 g (8 mmol) of (4) Was added. The 
mixture Was stirred for 90 hours at 45° C. Then H2S Was 
bubbled into the mixture for 10 min. The CuS Was removed 
by ?ltration. The solution Was evaporated. The residue Was 
dissolved in 1 ml of Water. The products Were precipitated 
from the solution using a mixture of ethanol and diethyl 
ether (1:1). The solid Was puri?ed by crystalliZation from 
ethanol (yield 32.3%). 
2) Synthesis of N,N-dimethyl canavanine 
N,N'—dimethyl-L—canaline 
536 mg (4 mmol) of canaline Was dissolved in 3 ml of 
Water, and 954 mg (12 mmol) of CuO Was added. The 
suspended solution Was boiled for 5 min. and stirred for tWo 
hours at 50° C. and 20 hours at RT. The excess CuO Was 
removed by ?ltration. The pH of the solution Was adjusted 
to 9.2. ZnCl2(0.586 g, 4.31 mmol) and (CH3)2NCN (0.302 
g, 4.31 mmol) Was dissolved in 4 ml of Water, and the 
solution Was added to the reaction mixture. The mixture Was 
stirred for 72 h. at 45° C. Then HZS Was bubbled into the 
solution for 20 min. The mixture Was ?ltered and evapo 
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rated. The residue Was puri?ed by DoWex 50><8 (NH4+). The 
product Was crystalliZed from ethanol (yield 30.3%). 
3) Preparation of 
NH; 2 
200 mg of dry L-canavanine Was dissolved in 50 ml of 
MeOH (abs.). Anhydrous HCl Was introduced into the 
solution for 10 min. Then the solution Was re?uxed for 1 h. 
With bubbling of HCl (20 bubble per min.). The solvent Was 
then evaporated. The residue Was recrystalliZed from methyl 
alcohol and diethyl ether, dried under vacuum, to yield 270 
mg (90%) of the methyl ester. 1H-NMR (D20 +TSP), 6: 
2.2—2.3 (2H. m); 3.72 (3H, s); 3.95—4.05 (2H, m); 4.15—4.22 
(1H, 
4) Preparation of 
NH; 2 
400 mg of dry L-canavanine Was dissolved in 60 ml of 
EtOH (abs.). Anhydrous HCl Was introduced into the solu 
tion for 10 min. Then the solution Was re?uxed for 2 h. With 
bubbling of HCl (20 bubble per min.). The solvent Was then 
evaporated. The residue Was recrystalliZed from methyl 
alcohol and diethyl ether, dried under vacuum, to yield 510 
mg (81%). 1H-NMR (DMSO-d6), 6: 1.19 (3H. t); 2.10—2.30 
(2H, m); 3.85—3.95 (2H, m); 4.05—4.15 (1H, m); 4.17 (2H, 
q); 7.75—7.85 (5H, broad). 
5) Preparation of 
0.490 g (1.77 mmol) of ethyl-L-canavanine ester (2HCl 
salt) Was dissolved in 5% NaHCO3 (25 ml) and 25 ml of 
acetonitrile Was added. 1.36 g (6 mmol) of di-t-butyl dicar 
bonate (97%) Was added. The mixture Was stirred for tWo 
days at RT. The acetonitrile Was evaporated, and 20 ml of 
Water Was added. The aqueous solution Was acidi?ed by 
using 10 citric acid, and extracted With DCM (3><30 ml). The 
DCM solution Was Washed With Water (4><30 ml), dried over 
NaZSO4 and evaporated. Yield of the N,N-diBOC derivative 
0.57 g (79.3%). 1H-NMR (CDCl3), 6: 1.22 (3H, t); 1.40 (9H, 
s); 1.42 (9H, s); 1.95—2.05 (1H, m); 2.05—2.15 (1H, m); 
3.82—3.90 (2H, m); 4.15 (2H, q); 4.35—4.40 (1H, m); 
5.35_5.40 [1H, d (broad)]; 5974.03 (1H, broad). 
6) Preparation of 
NH; 2 
2.76 g (20 mmol) of sodium phosphate monobasic Was 
dissolved in 20 ml of Water (the concentration is 1M). The 
pH Was adjusted to 7.8 With 2N NaOH. 0.277 g (1 mmol,) 
of ethyl-L-canavanine ester (2 HCl salt, MW: 277.11) Was 
added into the buffer solution. Then 10 ml of ethyl alcohol 
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Was added together With 0.247 g (1.1 rnol, MW 218) of 
t-butyl dicarbonate (97%). The solution Was stirred for 20 
hours at RT. Then the ethyl alcohol Was evaporated and 20 
ml of Water Was added. The aqueous solution Was extracted 
With DCM (3><30 ml). The DCM solution Was Washed With 
Water (3><20 ml), and dried over Na2SO4. The solvent Was 
evaporated. Yield of the N-BOC derivative Was 0.26 g 
(85%). 1H-NMR (CDCl3), 6: 1.26 (3H, t); 1.42 (9H, s); 
1.95—2.10 (1H, rn); 2.10—2.05 (1H, rn); 3.85—3.95 (2H, In); 
4.19 (2H, q); 4.35—4.45 (1H, rn); 5.30—5.40 (1H, broad). 
7) Preparation of 
NH; 
NHZ 
CH3CH2OOC 
10 
BenZoic acid (0.366 3 rnrnol) and 
N-hydroxysuccinirnide (0.345 g, 3 rnrnol) Was dissolved in 
10 ml. of CH3CN. Then DCC (0.618 g, 3 rnrnol) Was added. 
The mixture Was stirred for 24 h at RT. The DCU Was ?ltered 
out. 
Ethyl-L-canavanine dichloride salt (1.02 g, 0.36 rnrnol) 
Was dissolved in 10% NaHCO3 (30 ml). The solution Was 
cooled to 40 C. and the above C6H5—CO—OSu (in 15 ml. 
of CH3CN) Was added dropWise. The mixture Was stirred for 
12 h. at 4° C. and 12 h. at RT. Most of the solvent Was 
evaporated and 25 ml of Water Was added. The mixture Was 
extracted With ethyl acetate (3><30 ml). The ethyl acetate 
phase Was Washed With 5% NaHCO3 (1x20 ml.) and Water 
(1><20 ml), and dried over NaZSO4 (3 days at 4° C. to 
precipitate DCU completely). The NaZSO4 Was ?ltered out 
and the ethyl acetate Was evaporated. The residue Was 
dissolved in 10 ml. of ethyl alcohol and 1 ml. of HCl (6N) 
Was added. The ethyl alcohol Was evaporated and another 10 
ml. of ethyl alcohol Was added and evaporated again. The 
residue Was recrystallized from ethyl alcohol and diethyl 
ether, and dried under vacuum. 1H-NMR (DMSO-dG), 67 : 
8.90 (1H, d); 7.89 (2H, d); 7.65—7.80 (5H, broad); 7.42—7.60 
(3H, rn); 4.55—4.65 (1H, In); 4.12 (2H, q); 3.89 (2H, t); 
2.05—2.20 (1H, rn); 2.20—2.35 (1H, In); 1.19 (3H, t). 13C 
NMR (DMSO-dG): 6: 171.87 (C=O); 167.06 (C=O); 
158.36 (C=N); 133.67 (C—Ar); 131.90 (QH—Ar); 128.59 
(QH—Ar); 127.60 (QH—Ar); 73.34 (O—QH2CH3); 61.02 
(O—CH2CH2_); 49.70 (otQH); 28.88 ([3-CH2); 14.26 ( 
CH3). Calcd for C14H21N4O4Cl. 1A1 H2O: C:48.14; H: 6.18; 
N: 16.04; Cl: 10.16. Found: C: 48.20; H: 6.21; N: 15.54; Cl: 
10.43. 
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8) Preparation of 
|| / 
NH; 2 
O > NaHCO3 
NHZ 
-continued 
0 
H HO —OSuc 
C 
/ 1 NH; —N %
\ 
C 
// 
O 
0 
II 
c 
0 
|| / 
HOOC 
NaOH (8.0 g, 0.2 rnol) Was dissolved in 400 ml. of a 
mixture of Water and ethanol (1:1). After the solution Was 
cooled to RT, guanidine hydrochloride (9.5 g, 0.1 rnol) and 
di-t-butyl bicarbonate (Boc)2O Was added. The solution Was 
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stirred for 24 hours at RT. The ethanol Was evaporated. The 
Water solution Was extracted With ethyl acetate (5><100 ml). 
The ethyl acetate solution Was Washed With Water (2x20 ml), 
dried (Na2SO4) and the solvent removed to yield 3.1 g of N-t 
butyloxycarbonyl-guanidine [Boc—N=C(NH2)2], 78.0%. 
1H-NMR(CDCl3): 61.43 (9H, s); 6.10—6.20 (4H, broad). 
13C-NMR (DMSO-d6): 6: 163.216 (C=O); 162.68 (C=N); 
75.56 [—O—Q(CH3)3]; 28.23 (CH3). 
Boc-Glu(OH)-t-butyl (0.606 g, 2.0 mmol) Was dissolved 
in DCM (20 ml.). N-hydroxysuccinimide (HO—Suc) 
(0.253, 2.2 mmol) Was added. The solution Was cooled to 00 
C. DCC (0.453 g, 2.2 mmol) Was added. The solution Was 
stirred for 2 hours at 0° C. and 20 hrs at RT. The DCU Was 
?ltered out. The solvent Was evaporated. The residue Was 
dissolved in 5 ml. of DCM and left to stand for 24 hours at 
4° C. More DCU Was ?ltered out. The solvent Was evapo 
rated again. 
Boc—N=C(NH2)2 (0.477 g, 3 mmol) and TEA (0.648 g, 
5 mmol) Was dissolved in ethyl acetate (20 ml). The solution 
Was cooled to 0° C. Boc-Glu(OSu)-t-But in 10 ml. of ethyl 
acetate Was added. The mixture Was stirred for 2 hours at 0° 
C. and 20 hours at RT. 20 ml of ethyl acetate Was added and 
the solution Was Washed With 5% NaHCO3 (2><30 ml.), 
Water (1><30 ml), 5% citric acid (2><30 ml) and Water (3><30 
ml)m, dried over NaZSO4 and evaporated. The residue Was 
recrystalliZed from ethyl acetate and hexanes. Yield 0.70 g, 
78.8%. 1H-NMR(CDCl3): 61.44 (9H, s); 1.47(9H, s); 1.48 
(9H, s); 1.86—2.00 (1H, m); 2.10—2.24 (1H, m);2.34—2.42 
(2H, m); 4.16—4.25 (1H, 
Ethyl acetate (20 ml) and 36% HCl (10 ml) Was mixed 
and cooled to 0° C. Boc-Glu[N=C(NH2)2]-t-But (0.66 g, 
1.48 mmol) Was added. The solution Was returned to RT and 
stirred for 1 h. at RT. The solvent Was removed. 20 ml of 
ethyl alcohol Was added and the solution evaporated and 
dried under vacuum. The residue Was precipitated With ethyl 
alcohol and diethyl ether, and dried under vacuum. 1H-NMR 
(D20): 6: 2.17—2.27 (2H, m); 2.72—2.82 (2H, m); 3.93—4.00 
(1H, 13C-NMR(D2O): 6:177.90 (C=O); 175.50 
(C=O); 157.30 (C=N); 55.66 ((XQH); 35.27 (Y-QHZ); 27.13 
([3-CH2), Calcd for C6H14O3N4Cl2O: C: 26.68; H: 5.60; N: 
20.74; Cl: 26.25. Found: C: 26.71; H: 5.60; N: 20.77; Cl: 
26.17. 
9) Ethyl N°‘-benZoyl-L-canavanine ester 
BenZoic acid (0.366 g., 3 mmol) and 
N-hydroxysuccinimide (0.345 g, 3 mmol) Was dissolved in 
10 ml. of CH3CN. DCC (0.618 g, 3 mmol) Was then added. 
The mixture Was stirred for 24 h. at RT. The DCU Was 
?ltered off. 
Ethyl-L-canavanine ester dichloride salt (1.02 g, 0.36 
mmol) Was dissolved in 10% NaHCO3 (30 ml). The solution 
Was cooled to 4° C. and the above C6H5—CO—OSu (in 15 
ml. of CH3CN) Was added dropWise. The mixture Was 
stirred for 12 h. at 4° C. and 12 h. at RT. Most of the solvent 
Was evaporated, and 25 ml of Water Was added. The mixture 
Was extracted With ethyl acetate (3><30 ml). The ethyl acetate 
phase Was Washed With 5% NaHCO3 (1><20 ml.) and Water 
(1><20 ml.), and dried over NaZSO4 (3 days at 4° C. to 
precipitate the DCU completely). The NaZSO4 Was ?ltered 
off and the ethyl acetate Was evaporated. The residue Was 
dissolved in 10 ml. of ethyl alcohol, and 1 ml. of HCl (6N) 
Was added. The ethyl alcohol Was evaporated and another 10 
ml. of ethyl alcohol Was added and the solution evaporated 
again. The residue Was recrystalliZed from ethyl alcohol and 
diethyl ether, and dried under vacuum. 1H-NMR (DMSO 
d6), 6: 8.90 (1H, d); 7.89 (2H, d); 7.65—7.80 (5H, broad); 
7.42—7.60 (3H, m); 4.55—4.65 (1H, m); 4.12 (2H, q); 3.89 
(2H, t); 2.05—2.20 (1H, m); 2.20—2.35 (1H, m); 1.19 (3H, t). 
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13C-NMR (DMSO-d6): 6: 171.87 (C=O); 167.06 (C=O); 
158.36 (C=N); 133.67 (C—Ar); 131.90 (QH—Ar); 128.59 
(QH—Ar) 127.60 (QH—Ar); 73.34 (O—QH2CH3); 61.02 
(O—CH2CH2—) 49.70 (or-CH); 28.88 ([3-CH2); 14.26 
(CH3). Calcd for C14H21N4O4Cl. 1A1 H2O: C: 48.14, H: 6.18; 
N: 16.04; Cl: 10.16. Found: C: 48.20; H: 6.21; N: 15.54; Cl: 
10.43. 
Further, the compounds of the present invention are useful 
in pharmaceutical compositions for systemic administration 
to humans and animals in unit dosage forms, such as tablets, 
capsules, pills, poWders, granules, suppositories, sterile 
parenteral solutions or suspensions, sterile non-parenteral 
solutions or suspensions, oral solutions or suspensions, 
oil-in-Water or Water-in-oil emulsions and the like, contain 
ing suitable quantities of an active ingredient. 
For oral administration either solid or ?uid unit dosage 
forms can be prepared. The compounds are useful in phar 
maceutical compositions (Wt %) of the active ingredient 
With a carrier or vehicle in the composition of about 0.01 to 
99% and preferably about 5 to 15%. 
Either ?uid or solid unit dosage forms can be readily 
prepared for oral administration. For example, the com 
pounds can be mixed With conventional ingredients such as 
dicalciumphosphate, magnesium aluminum silicate, magne 
sium stearate, calcium sulfate, starch, talc, lactose, acacia, 
methyl cellulose and functionally similar materials such as 
pharmaceutical excipients or carriers. A sustained release 
formulation may optionally be used. Capsules may be for 
mulated by mixing the compound With a pharmaceutical 
diluent Which is inert and inserting this mixture into a hard 
gelatin capsule having the appropriate siZe. If soft capsules 
are desired a slurry of the compound With an acceptable 
vegetable, light petroleum, or other inert oil can be encap 
sulated by machine into a gelatin capsule. 
Suspensions, syrups and elixirs may be used for oral 
administration of ?uid unit dosage forms. A?uid preparation 
including oil may be used for oil soluble forms. Avegetable 
oil such as corn oil, peanut oil or safflower oil, for example, 
together With ?avoring agents, sWeeteners and any 
preservatives, produces an acceptable ?uid preparation. A 
surfactant may be added to Water to form a syrup for ?uid 
unit dosages. Hydro-alcoholic pharmaceutical preparations 
may be used having an acceptable sWeetener such as sugar, 
saccharine or a biological sWeetener and a ?avoring agent in 
the form of an elixir. 
Pharmaceutical compositions for parenteral administra 
tion can also be obtained using techniques standard in the art 
as set forth in Remington ’s Pharmaceutical Sciences, 18th 
Ed., 1989, Mack Publishing Company, incorporated herein 
by reference it its entirety. 
Accordingly, compositions suitable for administration are 
particularly included Within the invention. Parenteral solu 
tions or suspensions may be administered. If desired, a more 
concentrated sloW release form may be administered. 
Accordingly, incorporation of the active compounds in a 
sloW release matrix may be implemented for administering 
transdermally. The compounds may preferably be adminis 
tered at about 1 to 20% of the composition and more 
preferably about 5 to 15% Wt % of the active ingredient in 
the vehicle or carrier. 
The above and other drugs can be present in the reservoir 
alone or in combination form With pharmaceutical carriers. 
The pharmaceutical carriers acceptable for the purpose of 
this invention are the art knoWn carriers that do not 
adversely affect the drug, the host, or the material compris 
ing the drug delivery device. Suitable pharmaceutical car 
riers include sterile Water; saline, dextrose; dextrose in Water 
5,859,295 
23 
or saline; condensation products of castor oil and ethylene 
oxide combining about 30 to about 35 moles of ethylene 
oxide per mole of castor oil; liquid acid; loWer alkanols; oils 
such as corn oil; peanut oil, sesame oil and the like, With 
emulsi?ers such as mono- or di-glyceride of a fatty acid, or 
a phosphatide, e.g., lecithin, and the like; glycols; polyalky 
lene glycols; aqueous media in the presence of a suspending 
agent, for example, sodium carboxymethylcellulose; sodium 
alginate; poly(vinylpyrolidone); and the like, alone, or With 
suitable dispensing agents such as lecithin; polyoxyethylene 
stearate; and the like. The carrier may also contain adjuvants 
such as preserving, stabiliZing, Wetting, emulsifying agents 
and the like together With the penetration enhancer of this 
invention. 
The effective dosage for mammals may vary due to such 
factors as age, Weight, activity level or condition of the 
subject being treated. Typically, an effective dosage of a 
compound according to the present invention is about 0.1 to 
50 mg per kilogram of the subject’s Weight administered per 
day. Preferably about 25 to 50 mg per kilogram body Weight 
is administered per day. The required dose is less When 
administered parenterally, preferably about 25—30 mg per 
kilogram of body Weight per day may be administered 
intramuscularly. 
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The purpose of the above description and examples is to 
illustrate some embodiments of the present invention With 
out implying any limitation. It Will be apparent to those of 
skill in the art that various modi?cations and variations may 
be made to the composition and method of the present 
invention Without departing from the spirit or scope of the 
invention. All patents and publications cited herein are 
incorporated by reference in their entireties. 
We claim: 
1. Canavanine analog compound having a formula 
selected from the group consisting of: Formula 1 
HN 
R 
R5 
Wherein 
R3 is H2; —(CH3)2; or H-Boc 
R4 is —CH2CH3; or —CH3 
R5 is H; H-Boc; or 
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2. Acanavanine analog compound of claim 1 wherein said 
compound is selected from the group consisting of 
D-2- mino-3-(aminooxy)propionic acid dihydrochlo 
ride; 
D—2-Amino-3-(guanidinooxy)propionic acid; 
L-2-Amino-4- [assym-NG, NG-dimethyl (guanidinooxy)] 
butanoic acid; 
L-Canavanine Esters; 
Methyl L-2-amino—4-guanidinooxybutanoate; 
Ethyl L-2-amino—4-guanidinooxybutanoate; 
Isopropyl L-2-amino-4-guanidinooxybutanoate; 
n-Propyl L-2-amino—4-guanidinooxybutanoate; 
n-Butyl L-2-amino-4-guanidinooxybutanoate; 
n-Octyl-4-guanidinooxybutanoate, and mixtures thereof. 
3. A canavanine analog compound of claim 2, Wherein 
said L-Canavanine Esters are selected from the group con 
sisting of methyl, ethyl, isopropyl and n-propyl esters of 
L-canavanine. 
4. A pharmaceutical composition comprising a pharma 
ceutically effective amount of a compound according to 
claim 1 and a pharmaceutically acceptable carrier. 
5. A pharmaceutical composition according to claim 4 
Wherein said compound is selected from the group consist 
ing of 
D-2- mino-3-(aminooxy)propionic acid dihydrochlo 
ride; 
D—2-Amino-3-(guanidinooxy)propionic acid; 
L-2-Amino-4- [assym-NG, NG-dimethyl (guanidinooxy)] 
butanoic acid; 
L-Canavanine Esters; 
Methyl L-2-amino—4-guanidinooxybutanoate; 
Ethyl L-2-amino—4-guanidinooxybutanoate; 
Isopropyl L-2-amino-4-guanidinooxybutanoate; 
n-Propyl L-2-amino—4-guanidinooxybutanoate; 
n-Butyl L-2-amino-4-guanidinooxybutanoate; 
n-Octyl-4-guanidinooxybutanoate and mixtures thereof. 
6. A pharmaceutical composition according to claim 4 
Wherein said composition further comprises 5-?uorouracil. 
7. A pharmaceutical composition according to claim 4 
Wherein said composition further comprises a compound 
selected from the group consisting of (S) -2-aminoethyl-L 
cysteine, L-2-aZetidine carboxylic acid, 
L-selenomethionine, L-3—[N-hydroxy-4-oxypyridyl]—2 
aminopropionic acid and mixtures thereof. 
8. A method of treating cancerous tumor comprising the 
steps of administering a pharmaceutically effective amount 
of a compound according to claim 1 to a patient With cancer. 
9. A method of claim 8, Wherein said cancer is pancreatic 
cancer. 
10. A method of treating pancreatic cancer according to 
claim 1 Wherein said compound is selected from the group 
consisting of 
D-2- mino-3-(aminooxy)propionic acid dihydrochlo 
ride; 
D—2-Amino-3-(guanidinooxy)propionic acid; 
L-2-Amino-4- [assym-NG, NG-dimethyl (guanidinooxy)] 
butanoic acid; 
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L-Canavanine Esters; 
Methyl L-2-amino—4-guanidinooxybutanoate; 
Ethyl L-2-amino—4-guanidinooxybutanoate; 
Isopropyl L-2-amino-4-guanidinooxybutanoate; 
n-Propyl L-2-amino-4-guanidinooxybutanoate; 
n-Butyl L-2-amino-4-guanidinooxybutanoate; 
n-Octyl-4-guanidinooxybutanoate and mixtures thereof. 
11. A method of treating pancreatic cancer according to 
claim 10 Wherein said composition further comprises 
5-?uorouracil. 
12. A method of treating pancreatic cancer according to 
claim 10, Wherein said composition further comprises a 
compound selected from the group consisting of (S) 
2-aminoethyl-L-cysteine, L-2-aZetidine carboxylic acid, 
L-selenomethionine, L-3-[N-hydroxy-4-oxypyridyl]—2 
amino-propionic acid and mixtures thereof. 
13. A method of treating pancreatic cancer according to 
claim 10, Wherein said pharmaceutically effective amount is 
about 25 to 50 mg per kilogram body Weight a day. 
14. Canavanine analog compound having a formula 
NR3R4 Formula 4 
R1OOC CH2— (cH2),,—o —N =c 
i: NHR5 
RZHN H 
Wherein 
O Formula 2 
“ H2 
Formula 3 

